Innate Pharma (IPHA) Intangibles (2017 - 2024)

Innate Pharma has reported Intangibles for 8 years, with the latest figure at $128149.6 in Q2 2024.

• For the quarter ending Q2 2024, Intangibles fell 86.97% year-over-year to $128149.6; the trailing twelve-month figure through Jun 2024 stood at $128149.6 (down 86.97% YoY), and the FY2023 full-year result was $447591.0, down 71.81% from the prior year.
• Intangibles for Q2 2024 stood at $128149.6, down from $447591.0 in the prior quarter.
• The five-year high for Intangibles was $95.2 billion in Q2 2020, with the low at $128149.6 in Q2 2024.
• Historically, Intangibles has averaged $10.6 billion across 5 years, with a median of $46.2 million in 2022.
• The largest YoY upside for Intangibles was 8.4% in 2021 against a maximum downside of 99.94% in 2021.
• Innate Pharma's Intangibles stood at $55.2 million in 2020, then dropped by 8.4% to $50.6 million in 2021, then slumped by 96.86% to $1.6 million in 2022, then sank by 71.81% to $447591.0 in 2023, then sank by 71.37% to $128149.6 in 2024.
• The last three Intangibles figures came in at $128149.6 (Q2 2024), $447591.0 (Q4 2023), and $983298.7 (Q2 2023), per Business Quant data.